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Table A. Data available on asthma and wheeze in ALSPAC at all time-points. 
Data available 
Time-point (years) 
0.5 1.5 2.5 3.5 4.8 5.8 6.8 7.6 8.6 10.7 11.7 13.1 13.8 16.5 18.6 
Mother 
completed 
questionnaires 
Asthma 
in the 
past  12 
months 
      x x x x  x x   
Wheeze 
in the 
past 12 
months 
 
x x x x x x x x x x x x x x  
Doctor 
Diagno
sis of 
asthma 
ever 
       x  x   x   
Child 
completed 
questionnaires 
Asthma 
in the 
past  12 
months 
             x  
Wheeze 
in the 
past 12 
months 
 
             x x 
Doctor 
Diagno
sis of 
asthma 
ever 
             x  
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NUMBERS OF NEW CASES 
We also estimated incidence as the number of new cases per 1000 people, based on the number of 
new cases of asthma or wheeze at each time point. An individual was noted as a new case at the time-
point where they first respond positively to having asthma or wheeze symptoms. A sensitivity analysis 
using child-completed data at the 16.5 years time-point in place of the mother-completed data were 
also carried out. In the MCS, these estimates are not weighted for the study stratum design variable 
and clustering by ward is not taken into account. Due to the sampling on the MCS estimates cannot be 
interpreted as incidences. 
For ALSPAC the number of new cases of asthma in the past 12 months show males have a higher 
incidence until approximately 13.8 years. There were 29.9 (95% CI 24.8,36.0) new cases per 1000  in 
females at age 7.6, compared to 42.8 (95% CI 36.7,49.8) new cases per 1000 in males at the same age. 
The trend reverses at age 13.8 years with 22.5 (95% CI 17.7, 28.5) new female cases per 1000 females 
compared to 14.8 (95% CI 10.9,20.0) new male. Numbers of new cases for wheeze in the past 12 
months display a less clear pattern with error bars of females and males overlapping at multiple time-
points. Numbers of new cases for wheeze in the last 12 months start high (>170 cases per 1000 
individuals) in the first 2 years of life and then steadily decline. By age 18.6 years females have a 
markedly higher number of new cases than males at 129 (95% CI 110.6,150.1) per 1000 females 
compared to 58.1 (95% CI 40.4,83.0) per 1000 males. A sensitivity analysis using child-completed 
data at the 16.5 years time-point in place of the mother-completed data yielded very similar results. 
The number of new cases in the MCS calculated for asthma ever, wheeze ever and wheeze in the last 
12 months are higher for males in both measures until 7.2 years, with the number of new cases at 5.2 
years being 93.7 (95% CI 76.4,114.4) per 1000 males and 66.2 (95% CI 55.3,79.2) per 1000 females 
for asthma ever. However the difference between males and females becomes progressively smaller. 
By 10.7 years the difference appears smaller with 62.1 (95% CI 54.2,71.0) new cases per 1000 males 
and 49.7 (95% CI 49.7,55.1) per 1000 females for “asthma ever”. Similarly for both “wheeze in the 
last 12 months” and “wheeze ever”, where at 10.7 years, there were 81.2 (95% CI 71.1,92.7) new 
cases per 1000 males and 65 (95% CI 57.7,73.3) per 1000 females for wheeze ever.  
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Table B. Numbers of new cases for asthma in the last 12 months in ALSPAC at each time-point per 
1000 individuals. 
 Asthma last 12 months 
Age(years) Males [95% CI] Females [95% CI] 
7.6 42.77 [36.69,49.79] 29.9 [24.81,35.98] 
8.6 38.66 [32.81,45.51] 24.87 [20.24,30.51] 
10.7 41.48 [35.14,48.9] 30.14 [24.88,36.47] 
13.1 31.37 [25.52,38.5] 24.97 [19.96,31.21] 
13.8 14.75 [10.88,19.97] 22.47 [17.69,28.5] 
16.5* 26.98 [20.06,36.19] 39.94 [32.87,48.46] 
* offspring self-report 
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Table C. Numbers of new cases for wheeze in the last 12 months in ALSPAC at each time-point per 
1000 individuals. 
 Wheeze last 12 months 
Age (years) Males [95% CI] Females [95% CI] 
1.5 208.06 [195.93,220.72] 173.28 [162.14,185.01] 
2.5 128.12 [116.71,140.46] 97.72 [87.97,108.43] 
3.5 73.41 [64.17,83.86] 62.84 [54.64,72.18] 
4.8 74.89 [64.96,86.19] 50.08 [42.4,59.06] 
5.8 42.95 [34.98,52.65] 41.46 [34.05,50.39] 
6.8 25.93 [19.7,34.05] 24.53 [18.83,31.9] 
7.6 21.14 [15.54,28.69] 19.72 [14.61,26.59] 
8.6 52.58 [43.44,63.52] 30 [23.64,38.02] 
10.7 38.15 [30.02,48.37] 25.45 [19.44,33.25] 
11.7 33.71 [25.9,43.77] 30.7 [23.9,39.34] 
13.1 19.92 [13.87,28.53] 20.9 [15.24,28.59] 
13.8 15.98 [10.64,23.94] 17.97 [12.73,25.31] 
16.5 14.42 [8.85,23.42] 40.66 [31.68,52.03] 
18.6* 58.1 [40.36,82.96] 129.04 [110.59,150.05] 
  
* Offspring self-report 
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Table D. Numbers of new cases for asthma and wheeze in the MCS at each time-point per 1000 
individuals. 
 
  Asthma ever Wheeze ever Wheeze in the last 12 months 
Age 
(years) 
Males 
[95% CI] 
Females 
[95% CI] 
Males  
[95% CI] 
Females 
[95% CI] 
Males  
[95% CI] 
Females  
[95% CI] 
5.2 93.7 
[76.4,114.4] 
66.2 
[55.3,79.2] 
199.1 
[178.1,221.9] 
147.9 
[128.7,169.3] 
141.4 
[167.8,118.5] 
106.1 
[124.6,90.1] 
7.2 52.4 
[46.1,59.5] 
38.7 
[33.4,44.8] 
88.4 
[75.4,103.4] 
69.4 
[59.6,80.6] 
70.4 
[84.2,58.7] 
51.5 
[63.4,41.7] 
10.7 62.1 
[54.2,71] 
49.7 
[44.9,55.1] 
81.2 
[71.1,92.7] 
65  
[57.7,73.3] 
87.3 
[102.4,74.3] 
70 
[85.1,57.4] 
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Table E. Prevalence of asthma and wheeze in the last 12 months by sex modelled cross-sectionally 
across the available childhood time-points in ALSPAC. 
 Male OR [95% CI]  
for asthma in last 12 months* 
Male OR [95% CI]  
for wheeze in last 12 months* 
Mother completed  
time-points (years) 
0.5 NA 1.46 [1.35, 1.60] 
1.5 NA 1.41 [1.29, 1.53] 
2.5 NA 1.43 [1.30, 1.57]  
3.5 NA 1.29 [1.16, 1.43] 
4.8 NA 1.39 [1.25, 1.55] 
5.8 NA 1.34 [1.19, 1.51] 
6.8 1.31 [1.15, 1.49] 1.32 [1.16, 1.49] 
7.6 1.45 [1.26, 1.66] 1.48 [1.29, 1.71] 
8.6 1.43 [1.25, 1.64] NA 
10.7 1.45 [1.26, 1.66] 1.62 [1.41, 1.86] 
11.7 NA 1.47 [1.27, 1.69] 
13.1 1.38 [1.19, 1.59] 1.46 [1.25, 1.70] 
13.8 1.26 [1.09, 1.45] 1.30 [1.11, 1.51] 
16.5 NA 0.99 [0.83, 1.17] 
Child completed  
time-points (years) 
16.5 0.94 [0.79, 1.11] 0.71 [0.62, 0.83] 
18.6 NA 0.66 [0.55, 0.80] 
* In last 6 months for 1st time-point 
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Table F. Prevalence of asthma ever, wheeze ever and wheeze in the last 12 months by sex modelled 
cross-sectionally across the available childhood time-points in the Millennium Cohort Study. 
 Male OR [95% CI] 
Asthma ever 
Male OR [95% CI] 
Wheeze ever 
Male OR [95% CI] 
Wheeze in last 12 months 
Time-points (years) 
3.1 1.52 [1.37,1.68] 1.39 [1.3,1.49] 1.34 [1.25,1.45] 
5.2 1.51 [1.38,1.66] 1.51 [1.41,1.62] 1.44 [1.32,1.57] 
7.2 1.51 [1.37,1.67] 1.53 [1.4,1.66] 1.54 [1.38,1.72] 
10.7 1.42 [1.29,1.56] 1.44 [1.32,1.58] 1.57 [1.41,1.76] 
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Table G. Prevalence of asthma as defined by doctor diagnosis of asthma ever by sex modelled cross-
sectionally across the 4 available childhood time-points in ALSPAC. 
Time-point (years) Male OR [95% CI] 
for doctor diagnosis asthma 
7.6 1.36[1.22,1.51] 
10.7 1.42[1.27,1.58] 
13.8 1.25[1.12,1.40] 
Child-completed time-points (years) 
16.5 1.13 [0.99,1.28] 
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Table H. Statistics of the different wheezing phenotypes models attempted in the MCS, used to select 
the best fitting model. 
  
 3-class 4-class 5-class 6-class 
Number of 
parameters 
14 19 24 29 
BIC 15601 15586.074 15630.585 15675.097 
Entropy 0.953 0.894 0.893 0.966 
Lo-Mendell-Rubin 
Likelihood Ratio 
Test (Adjusted p-
value) 
<0.0001 <0.0001 1.00 0.50 
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Table I. Differences between the child-completed self-reports of wheeze in the last 12 months at 16.5 
years compared to the mother-completed questionnaires at the same age in ALSPAC, with percentage 
of total responders in each sex.  
 Child-completed 
Mother -
completed 
Male Female 
No Yes No Yes 
No 1,427(80.4%) 175(9.9%) 1,737(76%) 297(13%) 
Yes 44(2.5%) 128(7.2%) 56(2.5%) 195(8.5%) 
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Table J. Statistics of the different wheezing phenotypes models attempted in the MCS when stratified 
by sex. 
  
Females 
 3-class 4-class 5-class 6-class 
Number of parameters 14 19 24 29 
BIC 6873 6896.217 6937.396 6978.576 
Entropy 0.946 0.894 0.946 0.969 
Lo-Mendell-Rubin 
Likelihood Ratio Test 
(Adjusted p-value) 
0.0015 0.0001 0.50 0.50 
Males 
 3-class 4-class 5-class 6-class 
Number of parameters 14 19 24 29 
BIC 8717 8715.878 8756.787 8797.696 
Entropy 0.938 0.909 0.916 0.586 
Lo-Mendell-Rubin 
Likelihood Ratio Test 
(Adjusted p-value) 
<0.0001 <0.0001 0.46 0.53 
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Figure A. Estimated prevalence of wheezing at each time-point (from 3.1 to 10.7 years) for each of 
the four wheezing phenotypes, where green lines represent females and blue lines males. Figure is 
adapted to match Figure S4 reproduced from Granell et al. JACI 2016 with permission, for 
comparison. 
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Figure B. Reproduced with permission from Granell et al. JACI 2016 Figure 2. Estimated prevalence 
of wheezing at each time point from birth to 161⁄2 years for each of the 6 wheezing phenotypes 
identified by using latent class analysis in 12,303 participants with at least 2 observations of wheeze 
by sex. 
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Table K. Longitudinal logistic model of repeated wheeze and asthma measures using restricted cubic 
splines in ALSPAC and the MCS, adjusted interactions of sex with age in each spline. 
 
* Change in prevalence of asthma/wheeze per 1 year increase in age. 
** Change in prevalence of asthma/wheeze for males compared to females. 
†Measures used in the ALSPAC longitudinal models are wheeze in the last 12 months from 15 time-
points and asthma in the last 12 months from 7 time-points. 
†† Measures from the Millennium Cohort Study used in the longitudinal models are ever wheeze, 
ever asthma and wheeze in the last 12 months from 4 time-points. 
 
 Prevalence [95% CI] P-value 
ALSPAC†   
Wheeze 12 months†   
0.5-3.5 years 0.894 [0.86,0.93] 0.001 
3.5-6.8 years 0.821 [0.567,1.189] 0.295 
6.8-10.7 years 1.735 [0.656,4.59] 0.267 
10.7-16.7years 1.084 [0.424,2.772] 0.867 
Sex*age (0.5-3.5 years) 0.973 [0.924,1.024] 0.285 
Sex*age (3.5-6.8 years) 1.068 [0.652,1.749] 0.797 
Sex*age (6.8-10.7 years) 1.352 [0.369,4.958] 0.650 
Sex*age (10.7-16.7years) 0.275 [0.078,0.971] 0.045 
Sex** 1.495 [1.345,1.662] 0.001 
Asthma 12 months†   
6.8-10.8 years 0.974 [0.94,1.009] 0.136 
10.8-16.6 years 1.069 [1.011,1.131] 0.020 
Sex*age (6.8-10.8 years) 1.032 [0.984,1.083] 0.201 
Sex*age (10.8-16.7 years )  0.915 [0.847,0.989] 0.024 
Sex** 1.094 [0.723,1.657] 0.671 
MCS††   
Wheeze ever††   
3.1-5.5 years 0.953 [0.926,0.981] 0.001 
5.5-11.3 years 0.974 [0.923,1.028] 0.329 
Sex *age (3.1-5.5 years) 1.034 [0.994,1.075] 0.098 
Sex*age (5.5-11.3 years ) 0.947 [0.881,1.019] 0.142 
Sex** 1.261 [1.058,1.504] 0.010 
Asthma ever††   
3.1-5.5 years 1.107 [1.065,1.151] 0.001 
0.002 5.5-11.3 years 0.916 [0.855,0.981] . 1  
Sex *age (3.1-5.5 years) 0.999 [0.95,1.051] 0.963 
Sex*age (5.5-11.3 years ) 0.995 [0.909,1.089] 0.899 
Sex** 1.524 [1.2,1.935] 0.001 
Wheeze 12 months††   
3.1-5.5 years 0.945 [0.912,0.979] 0.002 
5.5-11.3 years 1.132 [1.06,1.21] 0.001 
Sex *age (3.1-5.5 years ) 1.028 [0.981,1.078] 0.26 
Sex*age (5.5-11.3 years ) 0.968 [0.886,1.058] 0.462 
Sex** 1.228 [0.999,1.51] 0.052 
